Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Rhea-AI Summary

Recursion (RXRX) reported its Q4 and FY2024 financial results, highlighting significant clinical and operational achievements. The company demonstrated promising safety and efficacy data for REC-617 in cancer treatment and REC-994 in cerebral cavernous malformations. Three new clinical studies were initiated across oncology, rare disease, and C. diff infection.

Key financial metrics for FY2024 include:

• Revenue: $58.8M (up from $44.6M in 2023)
• Cash position: $603.0M as of December 31, 2024
• Net loss: $463.7M (increased from $328.1M in 2023)

The company completed a strategic merger with Exscientia and delivered partnership milestones with Roche, Genentech, and Sanofi, generating $45M in cash inflows. Platform advancements include the launch of BioHive-2 supercomputer and development of new AI models. Cash runway is expected to extend into 2027.

Positive

• Revenue increased 32% YoY to $58.8M
• Strong cash position of $603M with runway into 2027
• Secured $45M in partnership milestone payments
• Promising clinical trial results for REC-617 and REC-994
• Launched three new clinical studies across different therapeutic areas

Negative

• Net loss increased 41% to $463.7M
• Q4 revenue declined 59% YoY to $4.5M
• Operating cash burn increased to $359.2M from $287.8M
• R&D expenses rose 30% to $314.4M
• G&A expenses increased 61% to $178.2M

Insights

Financial Analyst

Recursion's Q4 and fiscal 2024 results reveal a strategic transformation with mixed financial performance. Annual revenue increased 31.8% to $58.8 million, driven by the $30 million option exercise by Roche/Genentech for their neuroscience phenomap. However, Q4 revenue declined 58.7% year-over-year to $4.5 million, highlighting quarterly volatility in milestone-based partnership revenue.

The Exscientia merger has strengthened Recursion's balance sheet, with cash reserves of $603 million, extending runway into 2027. Yet this comes with significantly higher expenses – R&D increased 30.3% to $314.4 million and G&A jumped 60.8% to $178.2 million annually. Net losses widened to $463.7 million from $328.1 million.

The $45 million in partner milestone payments demonstrates validation of Recursion's platform. Their projected $100 million in merger synergies will be critical to moderate the accelerating cash burn of $359.2 million in 2024 vs $287.8 million in 2023. The company's real estate consolidation and Austrian operations carve-out (retaining 49% ownership) reflect necessary operational streamlining following the merger.

Despite advancing 10 clinical and preclinical programs, Recursion faces the challenge of converting scientific progress into sustainable revenue growth while managing their significant operational expenses. The partnership network with pharmaceutical giants provides validation but comes with execution risks in delivering on milestone expectations.

Biotechnology Specialist

Recursion's clinical portfolio is demonstrating promising signals across multiple therapeutic areas. REC-617, their AI-optimized CDK7 inhibitor, showed encouraging early efficacy with a durable partial response in metastatic ovarian cancer and stable disease in multiple solid tumor patients. This suggests potential for a best-in-class profile in a competitive CDK inhibitor landscape.

Their REC-994 program in cerebral cavernous malformations (CCM) represents a potential first-in-disease treatment, with Phase 2 data showing lesion volume reduction and trends toward symptom stabilization. The presentation at the International Stroke Conference indicates scientific recognition of this novel approach for an underserved condition.

The advancement of three new clinical programs is significant: REC-1245 (first-in-class RBM39 degrader) in solid tumors, REC-4881 for familial adenomatous polyposis, and REC-3964 for recurrent C. diff infection. This diversification across oncology, rare disease, and infectious disease demonstrates platform versatility.

The integration of Recursion's biology-centric platform with Exscientia's chemistry expertise creates complementary capabilities. Their computational infrastructure upgrades are substantial, with BioHive-2 supercomputer enabling foundation models like Phenom-2 and MolGPS that outperform industry benchmarks. The generation of 1.6 million transcriptomes and mapping of 1.4 million active ligands represents unprecedented biological data at scale.

Despite promising signals, challenges remain in translating platform capabilities to clinical success. The company must demonstrate that its AI-derived candidates can outperform traditionally-discovered drugs in efficacy, safety, and development timelines.

• Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous malformations
• Advanced three new clinical studies across oncology, rare disease, and recurrent C. diff infection with REC-1245, REC-4881, and REC-3964
• Delivered milestones for partners including the first neuro-phenomap for Roche and Genentech and two milestones for Sanofi for aggregate cash inflows of $45 million
• Completed business combination with Exscientia, cementing a position as a leading TechBio company

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and fiscal year ended December 31, 2024.

Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts giving analysts, investors, and the public the opportunity to ask questions of the company by submitting questions here: https://bit.ly/40UiVkb.

“In 2024, Recursion made a transformative leap with the largest TechBio merger in history, combining our pipeline, partnerships, people and platform to further accelerate the Recursion OS as the leading full-stack TechBio platform,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion. “With a portfolio of 10 clinical and preclinical programs, including both potential first-in-class and best-in-class therapies, we are driving towards faster and more effective drug development. These advances position us at the forefront of the next generation of medicine, where the impact will be measured not just in scientific breakthroughs through the power of our platform, but in real-world patient outcomes at scale.”

_{¹Includes preclinical programs (programs expected to enter the clinic within the next 18 months); ²Program milestones includes data readouts, preliminary data updates, regulatory submissions, trial initiation, etc.}

Summary of Business Highlights

Pipeline

• Clinical Results: Recursion demonstrated promising early efficacy data for two programs in 2024
  • REC-617: A potential best-in-class CDK7 inhibitor optimized using our AI platform, delivered early Phase 1/2 results demonstrating promising safety and efficacy, including a durable partial response in a late-stage metastatic ovarian cancer patient and stable disease across four other patients with solid tumors (e.g. CRC, NSCLC). These findings support further clinical development as the Company continues to explore its potential in combination regimens.
  • REC-994: A potential first-in-disease oral superoxide scavenger for symptomatic CCM, showing robust safety in chronic dosing in a Phase 2 study as well as a reduction in lesion volume as measured by MRI and trends towards symptom stabilization as evaluated by mRS. The data was featured in a late-breaking oral presentation at the 2025 International Stroke Conference. Next steps in this program will be informed by regulatory discussions and long-term extension data expected in 2025.
• Clinical Advancements and Regulatory Milestones:
  • Pipeline advanced with the initiation of three new clinical studies:
    • DAHLIA: Phase 1/2 trial investigating REC-1245, a potential first-in-class RBM39 degrader, in biomarker-enriched advanced solid tumors and lymphoma.
    • TUPELO: Phase 1b/2 trial investigating REC-4881 for familial adenomatous polyposis (FAP).
    • ALDER: Phase 2 trial investigating REC-3964, a potential first-in-class C. diff toxin B inhibitor, for preventing recurrent C. difficile infection.
  • Progressed additional programs:
    • REC-4539: received IND clearance for REC-4539 (LSD1 inhibitor) in small cell lung cancer
    • REC-3565: received CTA approval for REC-3565 (MALT1 inhibitor) in b-cell malignancies
    • REC-4209: progressed REC-4209 in idiopathic pulmonary fibrosis to IND-enabling studies

Partnerships

• Roche-Genentech:
  • Gastrointestinal-Oncology Advancements: In partnership with Roche and Genentech, Recursion has generated multiple whole-genome phenomaps with chemical perturbations across various disease-relevant cell types, enabling deeper insights into how different cellular contexts respond to gene knockouts and chemicals.
  • Neuro-specific CRISPR KO Phenomap: In partnership with Roche and Genentech, Recursion developed the first whole-genome CRISPR knockout map in neural iPSC cells, providing valuable data to identify potential new targets in neuroscience, a field which has historically suffered from limited new discoveries.
  • Milestones and Collaboration: The neuroscience phenomap work led to the exercise of a $30M option by Roche and Genentech in August 2024, and the collaboration is already moving forward with target validation projects.
• Sanofi:
  • Immunology & Oncology Achievements: Through this collaboration, Recursion is using its end-to-end integrated platform to discover and advance up to 15 novel targets in the oncology and immunology therapeutic areas.
    • In 2024, two programs advanced through initial milestones, generating $15M in aggregate payments from Sanofi.
• Bayer:
  • Oncology Achievements: Completed 25 multimodal oncology data packages utilizing the Recursion OS platform. Multiple programs are rapidly progressing to Lead Series nomination.
  • LOWE: Additionally, Bayer has adopted Recursion’s LOWE LLM-orchestrated workflow software to enhance their research capabilities.
• Merck KGaA (Darmstadt, Germany):
  • Ongoing alliance with Merck KGaA, Darmstadt, Germany is focused on leveraging Recursion’s discovery engine to identify first-in-class and best-in-class targets across oncology and immunology, driving innovation in these key therapeutic areas.

Platform

• ​​Full stack AI powered platform: Our constantly-evolving Recursion OS spans target discovery through clinical development, enabling efficient molecule design and testing for both first and best-in-class opportunities.
  • Integration of Exscientia’s Precision Chemistry Platform (Centaur) & Recursion OS:
    • Integrated Centaur into more than 10 design cycles for programs Recursion has previously partnered, with early validation work achieved and progress accelerating across multiple additional partnered programs.
    • The Recursion OS has been used to identify hit compounds in 7 immune-relevant targets or dual target pairs and early validation work has commenced to prepare reports for our partners.
    • ​​Recursion’s AI synthesis planning capability shows a 25% improved tractability assessment of AI-generated compounds over competitors.
  • Compute: Launched BioHive-2, the most powerful supercomputer owned by any biopharma company, enabling the training of industry-leading foundation models like Phenom-2, MolPhenix, and MolGPS.
  • Protein Target Data Layer: Mapped 1.4 million active ligands to binding pockets for structure-based drug discovery and target deconvolution.
  • Phenomics: Scaled phenomics experimental capabilities can now generate up to 16.2 (135 terabytes) million multi-timepoint brightfield images across up to 2.2 million experiments per week.
  • Transcriptomics: Generated >1.6M individual transcriptomes since its launch in 2023, with just under 1M generated in 2024 including building the world’s first genome-scale CRISPR knockout map in primary human cells.
  • InVivomics: Grew dataset to 1 million hours of video; 1 million hours of digital biomarkers and 149,000 environment data points.
  • LLM and Knowledge Graph Integration: Reduced manual effort by 60% for evidence collection for hit nomination packages supporting entry into hit-to-lead, through knowledge graphs and LLM-based data aggregation with further reduction expected with additional data layers.
• Breakthroughs in Foundation Models: Developed multimodal AI models like Phenom, MolPhenix, and MolGPS that accelerate Recursion’s ability to make high-confidence predictions in our therapeutics programs.
  • Phenom-2: A 1.9B-parameter model trained on 8B microscopy images, achieving 60% better linear separability of genetic perturbations and top performance in biological relationship recall and consistency.
  • MolPhenix: Delivers a 10X improvement over previous models in predicting the effects of molecules on cell assays and morphology.
  • MolGPS: A 3B-parameter model for molecular property prediction that outperforms the state of the art on 12 of 22 ADMET tasks in the Therapeutic data commons (TDC).
  • MolE: A new foundation model trained on 842M molecular graphs, surpassing earlier approaches by ranking first in 10 ADMET tasks in the TDC.

• Advancement in Causal AI Models & Emerging Focus on ClinTech: Transforming clinical development with Recursion’s ClinTech platform and models, focused on:
  • Utilizing AI models and Tempus data to build a patient stratification framework in small cell lung cancer (SCLC). This work is informing clinical strategies for the planned REC-4539 Phase I study commencing in the first half of 2025.
  • Automating key processes like site engagement and enrollment to accelerate patient matching and industrializing workflows to accelerate trial initiation.
  • Centralizing data systems to optimize clinical protocols, streamline operations, and significantly reduce costs and site burden.

Integration & Additional Corporate Updates

• Recursion completed the combination with Exscientia, becoming an industry-leading TechBio company, bringing together Recursion’s biology-first TechBio platform with Exscientia’s chemistry-first TechBio platform, and creating a compelling set of both first and best-in-class clinical programs and sector-leading partnerships.
• Recursion announced it will carve out its Austrian operations into a newly formed company, Alpha Biotechnology GmbH (“Alpha”). Recursion will have a 49% ownership in Alpha, a company leveraging a patient-tissue platform for the development of precision therapeutics for the treatment of hematological and solid cancers, while focusing its efforts and moderating spend.
• The company is on-track to sub-lease or otherwise simplify its real estate footprint post business combination to concentrate employees in a smaller number of sites while moderating spend.
• Recursion is maintaining its guidance of at least $100 million in synergies from the transaction, with a majority of the run rate amount achieved in 2025.
• The company will provide a comprehensive update in May 2025.

Fourth Quarter and Fiscal Year 2024 Financial Results

Financials reported for the full year 2024 include full year Recursion financials combined with financials from Exscientia post-business combination (November 20-December 31, 2024).

• Cash Position: Cash, cash equivalents and restricted cash were $603.0 million as of December 31, 2024, compared to $401.4 million as of December 31, 2023. On a combined basis, Recursion continues to expect cash runway to extend into 2027.
• Revenue: Total revenue, consisting primarily of revenue from collaborative agreements, was $4.5 million for the fourth quarter of 2024, compared to $10.9 million for the fourth quarter of 2023. Total revenue, consisting primarily of revenue from collaboration agreements, was $58.8 million for the year ended December 31, 2024, compared to $44.6 million for the year ended December 31, 2023. For the fourth quarter of 2024, the decrease of $6.4 million compared to the prior period was due to the timing of projects from the Company’s Roche and Genentech collaboration. For the year ended December 31, 2024 the increase of $14.3 million compared to the prior year was due to revenue recognized from our Roche and Genentech collaboration related to the completion of Recursion’s first neuroscience phenomap optioned by Roche and Genentech for $30 million.
• Pro Forma Revenue: The Company’s unaudited pro forma consolidated revenue is presented as if the Exscientia business combination had occurred on January 1, 2023. Pro forma revenue was $82.6 million for the year ended December 31, 2024, compared to $72.5 million for the year ended December 31, 2023.
• Research and Development Expenses: Research and development expenses were $98.3 million for the fourth quarter of 2024, compared to $69.5 million for the fourth quarter of 2023. Research and development expenses were $314.4 million for the year ended December 31, 2024, compared to $241.2 million for the year ended December 31, 2023. The increase in 2024 research and development expenses compared to the prior year was driven by our platform and personnel costs as the Company continues to expand and upgrade its platform, including chemical technology, machine learning and transcriptomics platform.
• General and Administrative Expenses: General and administrative expenses were $77.2 million for the fourth quarter of 2024 compared to $30.5 million for the fourth quarter of 2023. General and administrative expenses were $178.2 million for the year ended December 31, 2024, compared to $110.8 million for the year ended December 31, 2023. The increase in 2024 general and administrative expenses compared to the prior year was primarily driven by an increase in salaries and wages of $21.1 million, transaction costs of $20.5 million, inclusion of Exscientia’s results of $11.3 million and increases in software and lease expenses.
• Net Loss: Net loss was $178.9 million for the fourth quarter of 2024, compared to a net loss of $93.0 million for the fourth quarter of 2023. Net loss was $463.7 million for the year ended December 31, 2024, compared to a net loss of $328.1 million for the year ended December 31, 2023.
• Net Cash: Net cash used in operating activities was $115.4 million for the fourth quarter of 2024, compared to net cash used in operating activities of $74.1 million for the fourth quarter of 2023. Net cash used in operating activities was $359.2 million for the year ended December 31, 2024, compared to net cash used in operating activities of $287.8 million for the year ended December 31, 2023. The difference was primarily driven by (1) higher costs incurred for research and development and general and administrative due to Recursion’s expansion and upgraded capabilities and (2) Recursion’s combination with Exscientia.
  • Recursion noted that the change in Exscientia’s cash and cash equivalents and short term bank deposits from December 31, 2023 to November 20, 2024, the date of the close of the acquisition was $184 million. There were no material financings in this period¹:

(in thousands)	November 20, 2024		December 31, 2023			Change
Cash and cash equivalents	$	277,104		£	259,463
Short term bank deposits		-			103,586
Total - GBP	N/A			£	363,049
GBP to USD rate	N/A				1.27
Total - USD	$	277,104		$	461,072		$	(183,968	)

_{¹ December 31, 2023 amounts from the above table are from Exscientia’s 20-F Annual Filing. Recursion noted that Exscientia reported its results using International Financial Reporting Standards (IFRS) but that there are no IFRS to U.S. GAAP differences that would impact the measurement of Exscientia’s December 31, 2023 cash and cash equivalents and short term bank deposits amounts. Recursion believes this information helps provide additional information on Exscientia’s liquidity prior and up-to the acquisition and a more complete understanding of the Company’s liquidity, facilitating analysis of the Company’s results.}

About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Recursion Pharmaceuticals, Inc.
Consolidated Statements of Operations (unaudited)
(in thousands, except share and per share amounts)
		Three months ended							Years ended
		December 31,							December 31,
Revenue			2024			2023				2024			2023
	Operating revenue	$	4,511		$	10,624			$	58,488		$	43,876
	Grant revenue		35			267				351			699
Total revenue			4,546			10,891				58,839			44,575
Operating costs and expenses
	Cost of revenue		12,794			9,881				45,238			42,587
	Research and development		98,333			69,482				314,421			241,226
	General and administrative		77,186			30,458				178,184			110,822
Total operating costs and expenses			188,313			109,821				537,843			394,635
Loss from operations			(183,767	)		(98,930	)			(479,004	)		(350,060	)
	Other income, net		4,869			4,306				14,216			17,932
Loss before income tax benefit			(178,898	)		(94,624	)			(464,788	)		(332,128	)
	Income tax benefit		(7	)		1,628				1,127			4,062
Net loss		$	(178,905	)	$	(92,996	)		$	(463,661	)	$	(328,066	)
Per share data
Net loss per share of Class A, B and Exchangeable common stock, basic and diluted		$	(0.53	)	$	(0.42	)		$	(1.69	)	$	(1.58	)
Weighted-average shares (Class A, B and Exchangeable) outstanding, basic and diluted			336,035,980			233,158,161				274,207,146			207,853,702

Recursion Pharmaceuticals Inc
Consolidated Balance Sheets (unaudited)
(in thousands)
	December 31,			December 31,
	2024			2023
Assets
Current assets
Cash and cash equivalents	$	594,350		$	391,565
Restricted cash	3,045			3,231
Other receivables	49,166			3,094
Other current assets	67,708			40,247
Total current assets	714,269			438,137
Restricted cash, non-current	5,629			6,629
Property and equipment, net	141,063			86,510
Operating lease right-of-use assets	65,877			33,663
Financing lease right-of-use assets	26,273			_
Intangible assets, net	335,855			36,443
Goodwill	148,873			52,056
Deferred tax assets	1,934			_
Other assets, non-current	8,825			261
Total assets	$	1,448,598		$	653,699
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	21,613		$	3,953
Accrued expenses and other liabilities	81,872			46,635
Unearned revenue	61,767			36,426
Operating lease liabilities	13,795			6,116
Notes payable and financing lease liabilities	8,425			41
Total current liabilities	187,472			93,171
Unearned revenue, non-current	118,765			51,238
Operating lease liabilities, non-current	67,250			43,414
Notes payable and financing lease liabilities, non-current	19,022			1,101
Deferred tax liabilities	16,575			1,339
Other liabilities, non-current	4,732			_
Total liabilities	413,816			190,263
Commitments and contingencies
Stockholders’ equity
Common stock (Class A, B and Exchangeable)	4			2
Additional paid-in capital	2,473,698			1,431,056
Accumulated deficit	(1,431,283)			(967,622)
Accumulated other comprehensive loss	(7,637)			_
Total stockholders’ equity	1,034,782			463,436
Total liabilities and stockholders’ equity	$	1,448,598		$	653,699

Forward-Looking Statements

This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s positioning at the forefront of the next generation of medicine and achievement of faster and more effective drug development, expectations relating to early and late stage discovery, preclinical, and clinical programs, including timelines for commencement of and enrollment in studies, data readouts, and progression toward IND-enabling studies; expectations and developments with respect to licenses and collaborations, including option exercises by partners and additional partnerships, the value of data generated for the Roche-Genentech partnership, and the promising future of partnership programs, the progress of Bayer partnership programs to Lead Series nomination, the acceleration of progress across multiple partnered programs; prospective products and their potential future indications and market opportunities; developments with Recursion OS and other technologies; business and financial plans and performance, including guidance regarding expected synergies from the Exscientia combination, reduction of its real estate footprint, and the timing of a related comprehensive update; completion of the carve out of the Austrian entity and Recursion’s investment in Alpha Biotechnology GmbH; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/1c9c0293-61d6-4bdb-acf0-b96563e50f72
https://www.globenewswire.com/NewsRoom/AttachmentNg/20ff6a72-7f34-4217-bfde-d68945316fad

FAQ

What were Recursion's (RXRX) key clinical trial results in 2024?

REC-617 showed promising safety and efficacy in Phase 1/2 for cancer treatment, while REC-994 demonstrated safety and lesion volume reduction in Phase 2 for cerebral cavernous malformations.

How much revenue did RXRX generate in fiscal year 2024?

Recursion reported total revenue of $58.8 million for FY2024, up from $44.6 million in 2023.

What major partnerships did RXRX achieve milestones with in 2024?

Recursion delivered milestones with Roche, Genentech, and Sanofi, generating $45 million in cash inflows, including a $30M option exercise by Roche and Genentech.

What is RXRX's current cash position and expected runway?

Cash position was $603.0M as of December 31, 2024, with runway expected to extend into 2027.

How did the Exscientia merger impact RXRX's business in 2024?

The merger created a leading TechBio company, combining Recursion's biology-first platform with Exscientia's chemistry-first platform, with expected synergies of at least $100M.